FDA Proposes Excluding GLP-1 Drugs From Compounding List
The FDA has proposed to rescind the approval of the drug Tavneos, manufactured by Amgen. The proposal to rescind approval for Tavneos is being discussed in community forums. This move specifically targets drugs produced by Novo Nordisk and Eli Lilly. This move would prevent pharmacists from creating customized versions of these specific GLP-1 medications.
Topics
Developing
- 864d Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore.
- 864d Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
- 864d Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est.
- 864d Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium.
Sources · 7 independent
Hacker News
“FDA turns up heat on Amgen, proposing to rescind approval of Tavneos.”
Hacker News
“to rescind approval of Tavneos.”
Mastodon
“FDA proposes excluding Novo, Lilly GLP-1s from compounding list”
Mastodon
“FDA proposes excluding Novo, Lilly weight loss drugs from bulk compounding list in win for the companies”
Unlock the full story
Get a Pro subscription or above to see the live story progression and the full list of independent sources confirming each event as they happen.
Log in to upgrade